APREAprea Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Aprea Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APREEsta | $9M#8 | — | 0.2x#2 | — | — | 2.8%#7 | — | -32.8%#3 | — | — | -50.0%#4 | — |
| MTVA | $10M#2 | — | 1.5x#11 | — | — | 53.0%#2 | — | -190.2%#9 | — | — | -88.9%#13 | — |
| TOVX | $10M#3 | 0.2x#3 | 0.2x#1 | — | -100.0%#5 | 7.5%#5 | — | -42.1%#4 | -51.4%#1 | — | -45.0%#3 | — |
| PPCB | $37M#1 | 0.0x#1 | 3.7x#13 | — | — | -3136.6%#15 | — | -599.6%#14 | -533.3%#3 | — | -98.8%#15 | — |
| KALA | $10M#5 | 0.0x#2 | 1.1x#6 | — | — | 29.9%#4 | — | -298.3%#11 | -69.9%#2 | — | -99.9%#16 | — |
| AZTR | $10M#6 | 8.1x#5 | 1.3x#9 | — | -100.0%#5 | -22.2%#9 | — | -149.4%#6 | — | — | -79.7%#10 | — |
| FBLG | $10M#7 | 0.5x#4 | 2.1x#12 | — | — | -67.1%#13 | — | -402.2%#12 | -1409.7%#5 | — | -86.2%#11 | — |
| VTGN | $10M#4 | — | 0.4x#3 | 8.0x#3 | 161.1%#2 | -35.5%#12 | -5683.7%#4 | -284.7%#10 | -949.7%#4 | — | -92.1%#14 | — |
| ALZN | $9M#9 | — | 1.5x#10 | — | — | -94.3%#14 | — | -151.2%#7 | — | — | -30.0%#1 | — |
| ENSC | $9M#11 | — | — | 1.7x#1 | -2.8%#3 | -27.4%#10 | -202.1%#1 | — | — | — | -78.8%#9 | — |
| BFRG | $9M#12 | — | 1.2x#8 | 74.9x#5 | — | 7.1%#6 | -5652.4%#3 | -93.0%#5 | -5287.3%#6 | — | -64.3%#5 | — |
| CNSP | $9M#13 | — | 0.5x#4 | — | — | -7.6%#8 | — | -0.1%#2 | — | — | -34.3%#2 | — |
| XCUR | $9M#10 | — | 9.0x#14 | — | -100.0%#5 | 49.0%#3 | — | -506.2%#13 | — | — | -64.6%#6 | — |
| TRAW | $8M#14 | — | 0.7x#5 | 2.9x#2 | 1134.5%#1 | 105.5%#1 | -640.7%#2 | 79.2%#1 | — | — | -74.0%#7 | — |
| SNGX | $8M#15 | — | 1.2x#7 | 65.8x#4 | -85.8%#4 | -33.7%#11 | -9923.2%#5 | -167.0%#8 | — | 5#1 | -87.0%#12 | — |
| IMNN | $8M#16 | — | — | — | — | — | — | — | — | — | -74.4%#8 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice